AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'
Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars...To view the full article, register now.
Already a subscriber? Click here to view full article